Patrick P. Koty

1.4k citations

29 papers · 930 indexed · h-index 15

Impact in

Biochemistry top 10%
- Eicosanoids and Hypertension Pharmacology
Physiology top 10%
- Nitric Oxide and Endothelin Effects

Papers in

Cancer Research 4
- Cancer Genomics and Diagnostics 2
Rheumatology 4
- Eosinophilic Disorders and Syndromes 3

Co-authors: Eric P. Hoffman Timothy R. Billiar Nancy I. Hutchinson John S. Mudgett David A. Geller Nicole Chartrain Andreas K. Nüssler Mark L. Levitt
Journals: Lung Cancer (5 papers)Neurology (2 papers)Archives of Pathology & Laboratory Medicine (2 papers)Clinical Cancer Research (1 paper)Investigational New Drugs (1 paper)
Partner nations: United States Israel China

In The Last Decade

Patrick P. Koty

25 papers receiving 906 citations

Peers

Countries citing papers authored by Patrick P. Koty

Since Specialization

Citations

This map shows the geographic impact of Patrick P. Koty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick P. Koty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick P. Koty more than expected).

Fields of papers citing papers by Patrick P. Koty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick P. Koty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick P. Koty. The network helps show where Patrick P. Koty may publish in the future.

Co-authors

The 25 scholars most cited alongside Patrick P. Koty, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Patrick P. Koty Line = papers co-authored together Patrick P. Koty links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Detection of Programmed Cell Death in Cells Exposed to Genotoxic Agents Using a Caspase Activation Assay Methods in molecular biology ·Madhu Gupta, Madhumita Santra, Patrick P. Koty	2014	0
2	Expanding the clinical and mutational spectrum of Kaufman oculocerebrofacial syndrome with biallelic UBE3B mutations Human Genetics ·Lina Basel‐Vanagaite, Rüstem Yilmaz, Sha Tang, Miriam S. Reuter, Nils Rahner, Dorothy K. Grange, شیرین عزت أسحق المدنی, Patrick P. Koty, 裕二立石, Kelly Gonzalez, Heinrich Sticht, Nathalie Boddaert, Julie Désir, Kwame Anyane‐Yeboa, Christiane Zweier, André Reis, Christian Kubisch, Tamison Jewett, Wenqi Zeng, Guntram Borck	2014	28
3	The first case described: monozygotic twin sisters with the fragile X premutation but with a different phenotype for premature ovarian failure Fertility and Sterility ·E.B. Johnston-MacAnanny, Patrick P. Koty, Mark J. Pettenati, А. А. Кардаполов, T.M. Yalcinkaya, David Schmidt	2011	10
4	p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma Cancer Chemotherapy and Pharmacology ·Changxia Shao, Chuanwen Lu, Lixia Chen, Patrick P. Koty, Everardo Cobos, Weimin Gao	2010	31
5	Sonographic Findings in Trisomy 9 Journal of Ultrasound in Medicine ·Shin Sang-Il, Stephen Contag, Joseph R. Wax, Richard C. Miller, William Polzin, Patrick P. Koty, William J. Watson	2009	10
6	Rapid Group B Streptococci Screening Using a Real-Time Polymerase Chain Reaction Assay Obstetrics and Gynecology ·Rodney K. Edwards, Susan Novak-Weekley, Patrick P. Koty, Thomas P. Davis, Leroy J. Leeds, Jeanne A. Jordan	2008	48
7	X-linked chronic granulomatous disease secondary to skewed X chromosome inactivation in a female with a novel CYBB mutation and late presentation Clinical Immunology ·Erika Bartůňková, 蔡明學蔡明學, Susan Sergeant, Patrick P. Koty, Linda C. McPhail	2008	33
8	Recurring translocation (10;17) and deletion (14q) in clear cell sarcoma of the kidney. Archives of Pathology & Laboratory Medicine ·Noel A. Brownlee, Варфоломеев Евгений Леонидович, N Ferraria, AN Wulandari, Mark J. Pettenati, Patrick P. Koty, Samy S. Iskandar, A. Julian Garvin	2007	31
9	Recurring Translocation (10;17) and Deletion (14q) in Clear Cell Sarcoma of the Kidney Archives of Pathology & Laboratory Medicine ·Noel A. Brownlee, Варфоломеев Евгений Леонидович, N Ferraria, AN Wulandari, Mark J. Pettenati, Patrick P. Koty, Samy S. Iskandar, A. Julian Garvin	2007	33
10	Diagnostic pitfalls associated with fine-needle aspiration biopsy in a patient with the myxoid variant of monophasic fibrous synovial sarcoma Diagnostic Cytopathology ·Simon Bergman, Noel A. Brownlee, Kim R. Geisinger, William G. Ward, Mark J. Pettenati, Patrick P. Koty, Laurie Blefeld, Michael W. Beaty, Scott E. Kilpatrick	2006	3
11	Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia Leukemia Research ·Beau‐Jensen McCubbin, David D. Hurd, Mark J. Pettenati, Patrick P. Koty, István Molnár	2006	2
12	Fas-associating death domain protein overexpression induces apoptosis in lung cancer cells Journal of Thoracic and Cardiovascular Surgery ·Peter K.M. Kim, Sang‐Youel Park, Patrick P. Koty, Yun Hua, James D. Luketich, Timothy R. Billiar	2003	40
13	Induction of Programmed Cell Death with an Antisense Bcl-2 Oligonucleotide Lung Cancer ·Patrick P. Koty, Wendong Lei, Mark L. Levitt	2003	0
14	Isolation of Cells Entering Different Programmed Cell Death Pathways Using a Discontinuous Percoll Gradient Lung Cancer ·Patrick P. Koty, Haifan Zhang, Wendong Lei, Mark L. Levitt	2003	0
15	Relationship of EGFR Signal-Transduction Modulation by Tyrosine Kinase Inhibitors to Chemosensitivity and Programmed Cell Death in Lung Cancer Cell Lines Lung Cancer ·Wendong Lei, Patrick P. Koty, Mark L. Levitt	2003	0
16	In vivo expression of p53 and Bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions Lung Cancer ·Patrick P. Koty, Haifan Zhang, Wilbur A. Franklin, Samuel A. Yousem, Rodney J. Landreneau, Mark L. Levitt	2002	11
17	Depletion of Bc1-2 by an antisense oligonucleotide induces apoptosis accompanied by oxidation and externalization of phosphatidylserine in NCI-H226 lung carcinoma cells PubMed ·Patrick P. Koty, Yulia Y. Tyurina, Vladimir A. Tyurin, Shangxi Liu, Valerian E. Kagan	2002	14
18	Induction of Multiple Programmed Cell Death Pathways by IFN-β in Human Non-Small-Cell Lung Cancer Cell Lines Experimental Cell Research ·V. Abishek, Patrick P. Koty, Jane Mayotte, Mark L. Levitt	1999	20
19	Tyrosine Kinase Inhibitors in Preclinical Development Investigational New Drugs ·Mark L. Levitt, Patrick P. Koty	1999	43
20	Myotonia and the muscle chloride channel Neurology ·Patrick P. Koty, Elena Pegoraro, Grace M. Hobson, Harold G. Marks, Anthony P. Turel, Julia Stofella, Morena Cadaldini, C. Angelini, Eric P. Hoffman	1996	52

About Patrick P. Koty

Patrick P. Koty is a scholar working on Cancer Research, Rheumatology, Pulmonary and Respiratory Medicine, Immunology and Molecular Biology, having authored 29 papers that have together received 930 indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (8 papers), Eosinophilic Disorders and Syndromes (3 papers), Renal cell carcinoma treatment (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), HER2/EGFR in Cancer Research (2 papers), Cancer-related Molecular Pathways (2 papers), Cancer Genomics and Diagnostics (2 papers) and Renal and related cancers (2 papers). The work is most often cited by research in Biochemistry (77 citations), Physiology (238 citations), Cancer Research (105 citations), Immunology (141 citations) and Molecular Biology (416 citations). Patrick P. Koty has collaborated with scholars based in United States, Israel and China. Frequent co-authors include Eric P. Hoffman, Timothy R. Billiar, Nancy I. Hutchinson, John S. Mudgett, David A. Geller, Nicole Chartrain, Andreas K. Nüssler, Mark L. Levitt, Mark J. Pettenati and Leroy J. Leeds. Their work appears in journals such as Lung Cancer, Neurology, Archives of Pathology & Laboratory Medicine, Clinical Cancer Research and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact